These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33486476)

  • 1. Development and Validation of a New Scoring Tool to Evaluate the Clinical Evolution of Adult Patients with Nonsegmental Vitiligo.
    Peralta-Pedrero ML; Herrera-Bringas D; Torres-González KS; Morales-Sánchez MA; Jurado Santa-Cruz F; Cruz-Avelar A
    Dermatology; 2021; 237(6):952-960. PubMed ID: 33486476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a patient-reported outcome measure in vitiligo: The Self Assessment Vitiligo Extent Score (SA-VES).
    van Geel N; Lommerts JE; Bekkenk MW; Prinsen CA; Eleftheriadou V; Taieb A; Picardo M; Ezzedine K; Wolkerstorfer A; Speeckaert R;
    J Am Acad Dermatol; 2017 Mar; 76(3):464-471. PubMed ID: 27887798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of the Vitiligo Extent Score (VES): an International Collaborative Initiative.
    van Geel N; Lommerts J; Bekkenk M; Wolkerstorfer A; Prinsen CAC; Eleftheriadou V; Taïeb A; Picardo M; Ezzedine K; Speeckaert R
    J Invest Dermatol; 2016 May; 136(5):978-984. PubMed ID: 26827762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo.
    Komen L; da Graça V; Wolkerstorfer A; de Rie MA; Terwee CB; van der Veen JP
    Br J Dermatol; 2015 Feb; 172(2):437-43. PubMed ID: 25278165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review of Clinimetric Instruments to determine the severity of Non-segmental Vitiligo.
    Peralta-Pedrero ML; Morales-Sánchez MA; Jurado-Santa Cruz F; De la Torre-García ME; Cruz-Peralta ES; Olguín-García MG
    Australas J Dermatol; 2019 Aug; 60(3):e178-e185. PubMed ID: 30820942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a physician global assessment tool for vitiligo extent: Results of an international vitiligo expert meeting.
    van Geel N; Wolkerstorfer A; Ezzedine K; Pandya AG; Bekkenk M; Grine L; Van Belle S; Lommerts JE; Hamzavi I; Harris JE; Eleftheriadou V; Esmat S; Kang HY; Kumarasinghe P; Lan CE; Parsad D; Raboobee N; Flora Xiang L; Suzuki T; Prinsen CA; Taieb A; Picardo M; Speeckaert R;
    Pigment Cell Melanoma Res; 2019 Sep; 32(5):728-733. PubMed ID: 30945409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliability, Validity and Feasibility of the Vitiligo Extent Score (VES) and Self-Assessment Vitiligo Extent Score (SA-VES) Among Vitiligo Patients: A Cross-Cultural Validation.
    Chaweekulrat P; Silpa-Archa N; Apinuntham C; Chaiyabutr C; Wongpraparut C
    Clin Cosmet Investig Dermatol; 2021; 14():949-957. PubMed ID: 34349539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a Patient Global Assessment for extent, severity and impact to define the severity strata for the Self Assessment Vitiligo Extent Score (SA-VES).
    van Geel N; Uitentuis SE; Zuidgeest M; Wolkerstorfer A; Bekkenk MW; Moock C; Van Goethem C; Verlaeckt E; Smet C; Grine L; Speeckaert R
    J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):216-221. PubMed ID: 32452565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of interrupted versus continuous narrowband ultraviolet B phototherapy in nonsegmental vitiligo treatment: A prospective randomized comparative study.
    Anbar TS; Mohammed SS; Mohamed DM; Abdel-Rahman AT
    Dermatol Ther; 2019 Nov; 32(6):e13117. PubMed ID: 31606939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the dynamic changes in vitiligo: reliability and validity of the Vitiligo Disease Activity Score (VDAS) and Vitiligo Disease Improvement Score (VDIS).
    van Geel N; Depaepe L; Vandaele V; Mertens L; Van Causenbroeck J; De Schepper S; Van Coile L; Van Reempts A; De Vos AS; Papeleu J; Hoorens I; Mertens D; Wolkerstorfer A; Lommerts JE; Speeckaert R
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1334-1341. PubMed ID: 35398942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitiligo impact scale: an instrument to assess the psychosocial burden of vitiligo.
    Krishna GS; Ramam M; Mehta M; Sreenivas V; Sharma VK; Khandpur S
    Indian J Dermatol Venereol Leprol; 2013; 79(2):205-10. PubMed ID: 23442459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the diagnostic criteria for segmental vitiligo.
    Gupta P; Khaitan BK; Ramam M; Ramesh V; Sundharam JA; Malhotra A; Gupta V; Sreenivas V
    Indian J Dermatol Venereol Leprol; 2020; 86(6):656-662. PubMed ID: 32611883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Vitiligo Among Adults in the United States.
    Gandhi K; Ezzedine K; Anastassopoulos KP; Patel R; Sikirica V; Daniel SR; Napatalung L; Yamaguchi Y; Baik R; Pandya AG
    JAMA Dermatol; 2022 Jan; 158(1):43-50. PubMed ID: 34787670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Vitiligo Impact Patient Scale (VIPs): Development and Validation of a Vitiligo Burden Assessment Tool.
    Salzes C; Abadie S; Seneschal J; Whitton M; Meurant JM; Jouary T; Ballanger F; Boralevi F; Taieb A; Taieb C; Ezzedine K
    J Invest Dermatol; 2016 Jan; 136(1):52-8. PubMed ID: 26763423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of correlation of the patient-derived Vitiligo Disease Activity Index with the clinician-derived Vitiligo Area Scoring Index.
    Coias J; Hynan LS; Pandya AG
    J Am Acad Dermatol; 2018 May; 78(5):1015-1016. PubMed ID: 29180097
    [No Abstract]   [Full Text] [Related]  

  • 16. Development and validation of the fingertip unit for assessing Facial Vitiligo Area Scoring Index.
    Bae JM; Zubair R; Ju HJ; Kohli I; Lee HN; Eun SH; Lyons AB; Vellaichamy G; Han TY; Lim HW; Hamzavi IH
    J Am Acad Dermatol; 2022 Feb; 86(2):387-393. PubMed ID: 34246695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study.
    Khemis A; Fontas E; Moulin S; Montaudié H; Lacour JP; Passeron T
    J Invest Dermatol; 2020 Aug; 140(8):1533-1537.e2. PubMed ID: 32004567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Halo nevi association in nonsegmental vitiligo affects age at onset and depigmentation pattern.
    Ezzedine K; Diallo A; Léauté-Labrèze C; Seneschal J; Mossalayi D; AlGhamdi K; Prey S; Bouchtnei S; Cario-André M; Boralevi F; Jouary T; Taieb A
    Arch Dermatol; 2012 Apr; 148(4):497-502. PubMed ID: 22508876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitiligo Treatment Impact score (VITs): development and validation of a vitiligo burden of treatment questionnaire using the ComPaRe Vitiligo e-cohort.
    Shourick J; Seneschal J; Andreu N; Meurant JM; Pane I; Ravaud P; Tran VT; Ezzedine K
    J Eur Acad Dermatol Venereol; 2022 Feb; 36(2):279-285. PubMed ID: 34657353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of vitiligo treatment success.
    Batchelor JM; Tan W; Tour S; Yong A; Montgomery AA; Thomas KS
    Br J Dermatol; 2016 Feb; 174(2):386-94. PubMed ID: 26409256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.